Trial Profile
A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUPS STUDY ON EFFICACY AND SAFETY OF NAC 600 MG DAILY AND NAC 1200 MG DAILY AS MUCOLYTIC AGENT IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE COPD EXACERBATION.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 May 2016
Price :
$35
*
At a glance
- Drugs Acetylcysteine (Primary)
- Indications Acute exacerbations of chronic bronchitis
- Focus Therapeutic Use
- Sponsors Zambon Company SpA
- 21 Jun 2011 New trial record